CRF Inc., the world leader in electronic Patient
Reported Outcomes (e-PRO) and wireless data collection solutions for
the biopharmaceutical industry, announced today that the company's
commitment to innovation and the development of cutting-edge ePRO
technology has helped pharmaceutical company partners stay ahead of
the critical path. The FDA created the Critical Path Initiative in
order to modernize the scientific drug discovery and development
process to encourage innovation, safety and efficiency.
The Critical Path Initiative calls for technologies and actions that can increase the efficiency of the discovery to market biopharmaceutical process, and clinical trial tools have demonstrated they have a pivotal role to play. CRF Inc.'s TrialMax is the most widely used ePRO solution in the world and provides real-time patient monitoring, outstanding data accuracy, unrivaled flexibility, increased patient safety, and enhanced efficiency. CRF technology helps pharmaceutical companies stay ahead of the critical path by enabling companies to run clinical trials more quickly and with greater safety.
"CRF is proud to provide the leading eDiary technology that has helped enable pharmaceutical companies to stay ahead of the trials critical path," said Pamela McNamara, Chief Executive Officer of CRF Inc. "Within the competitive environment of pharmaceutical development and clinical trial management, technologies and programs that allow companies to stay ahead of the critical path ensure a level of success in the development of these solutions and a guarantee that patients will have access to more innovative and safer products at an accelerated rate."
CRF utilizes the following methods in its eDiary technology to help companies stay ahead of the critical path:
-- Advanced Technology: iPrompt(TM) combines CRF's pharmaceutical technology experience with specialist therapeutic skills. Its unique capabilities enable marketing, clinical and safety executives to have more actionable, accurate and relevant data direct from the patient faster and with less cost than traditional methods. The technology utilizes handheld devices, text messaging, email and smart pill packaging to deliver the highest ROI and patient satisfaction.
-- Precise Study Guidelines: CRF's innovative TrialMax technology has a planning component that trial organizers use to confirm the scope and expectations of a project, identify any requirements or changes in scope, and set and communicate initial timelines and deliverables. TrialMax Planning also helps study coordinators to identify single sponsor eDiary decision-maker on all eDiary design matters.
-- Study Approval: CRF's TrialMax also helps customers meet aggressive Ethics Committee/IRB approval schedules through the powerful TrialStudio screen reports that rapidly approve screen design and localization text. CRF Inc. designs a working prototype with data sending to demonstrate benefits at investigators meetings.
-- Global Capabilities: On the global stage, CRF's positions customers ahead of the critical path by providing global multi-lingual helpdesk support that is trained on devices as well as protocol specific implementations of eDiaries as well as multi-media training and simulations for monitors and site staff to assure adoption and ease of use.
-- High Quality Data: CRF's Quality Management System (QMS) process ensures high level of quality not only in deliverables but also in processes, communications and customer service. It also allows for constant review and improvement along with built-in processes to reduce overall time to delivery.
About CRF Inc.
CRF Inc. is the leading global provider of electronic Patient Reported Outcomes (e-PRO) and wireless data collection solutions for the biopharmaceutical industry. Through innovative technology and a thorough understanding of drug development and mobile computing, the company is driving the change to safer and more efficient paper-free clinical trials. CRF Inc.'s technology has been used by more than 100,000 patients across 58 countries in 57 languages for 40 indications. The company has demonstrated the industry's highest patient compliance rates -- an average 95 percent compliance through Phase I, II, III and IV clinical trials -- and unmatched patient and research site acceptance.
CRF Inc.'s award-winning product, TrialMax(TM), is a flexible and customizable e-PRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety. Its unique features enable clinical trial sponsors to collect more valuable data faster and conduct complex clinical trials with greater flexibility than other e-PRO solutions. CRF Inc.'s experience combined with its dedication to ensuring the highest quality and most responsive customer service has made the company the biopharmaceutical industry's most trusted partner.
For more information, please visit www.crfhealth.com.
The Critical Path Initiative calls for technologies and actions that can increase the efficiency of the discovery to market biopharmaceutical process, and clinical trial tools have demonstrated they have a pivotal role to play. CRF Inc.'s TrialMax is the most widely used ePRO solution in the world and provides real-time patient monitoring, outstanding data accuracy, unrivaled flexibility, increased patient safety, and enhanced efficiency. CRF technology helps pharmaceutical companies stay ahead of the critical path by enabling companies to run clinical trials more quickly and with greater safety.
"CRF is proud to provide the leading eDiary technology that has helped enable pharmaceutical companies to stay ahead of the trials critical path," said Pamela McNamara, Chief Executive Officer of CRF Inc. "Within the competitive environment of pharmaceutical development and clinical trial management, technologies and programs that allow companies to stay ahead of the critical path ensure a level of success in the development of these solutions and a guarantee that patients will have access to more innovative and safer products at an accelerated rate."
CRF utilizes the following methods in its eDiary technology to help companies stay ahead of the critical path:
-- Advanced Technology: iPrompt(TM) combines CRF's pharmaceutical technology experience with specialist therapeutic skills. Its unique capabilities enable marketing, clinical and safety executives to have more actionable, accurate and relevant data direct from the patient faster and with less cost than traditional methods. The technology utilizes handheld devices, text messaging, email and smart pill packaging to deliver the highest ROI and patient satisfaction.
-- Precise Study Guidelines: CRF's innovative TrialMax technology has a planning component that trial organizers use to confirm the scope and expectations of a project, identify any requirements or changes in scope, and set and communicate initial timelines and deliverables. TrialMax Planning also helps study coordinators to identify single sponsor eDiary decision-maker on all eDiary design matters.
-- Study Approval: CRF's TrialMax also helps customers meet aggressive Ethics Committee/IRB approval schedules through the powerful TrialStudio screen reports that rapidly approve screen design and localization text. CRF Inc. designs a working prototype with data sending to demonstrate benefits at investigators meetings.
-- Global Capabilities: On the global stage, CRF's positions customers ahead of the critical path by providing global multi-lingual helpdesk support that is trained on devices as well as protocol specific implementations of eDiaries as well as multi-media training and simulations for monitors and site staff to assure adoption and ease of use.
-- High Quality Data: CRF's Quality Management System (QMS) process ensures high level of quality not only in deliverables but also in processes, communications and customer service. It also allows for constant review and improvement along with built-in processes to reduce overall time to delivery.
About CRF Inc.
CRF Inc. is the leading global provider of electronic Patient Reported Outcomes (e-PRO) and wireless data collection solutions for the biopharmaceutical industry. Through innovative technology and a thorough understanding of drug development and mobile computing, the company is driving the change to safer and more efficient paper-free clinical trials. CRF Inc.'s technology has been used by more than 100,000 patients across 58 countries in 57 languages for 40 indications. The company has demonstrated the industry's highest patient compliance rates -- an average 95 percent compliance through Phase I, II, III and IV clinical trials -- and unmatched patient and research site acceptance.
CRF Inc.'s award-winning product, TrialMax(TM), is a flexible and customizable e-PRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety. Its unique features enable clinical trial sponsors to collect more valuable data faster and conduct complex clinical trials with greater flexibility than other e-PRO solutions. CRF Inc.'s experience combined with its dedication to ensuring the highest quality and most responsive customer service has made the company the biopharmaceutical industry's most trusted partner.
For more information, please visit www.crfhealth.com.
© 2006 Business Wire
